Study on predicting treatment response in liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with liver cancer (HCC) through a biopsy
- You have at least one tumor that is 1 cm or larger
- You are scheduled to receive a liver artery treatment (HAIC or TACE) plus immunotherapy
- Your liver function is good (Child-Pugh class A)
- You are able to perform daily activities without much help (ECOG 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
This trial looks at how well a prediction model can estimate the chances of successfully shrinking liver cancer with certain treatments. It includes patients with larger or multiple tumors in the liver, as long as the cancer has not spread to other parts of the body.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This study looks at a 29-gene test to see if it can predict how well liver cancer responds to targeted therapy plus immunotherapy. If you have liver cancer and are getting this type of treatment, your stored tumor sample might help researchers learn more.
This study looks at blood cells from people with liver cancer (HCC) to see if we can predict early whether immunotherapy will work for them. It's a research study that involves blood tests during your normal care.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.